Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067490 | 0.78 | CXCR2 (0.48) | CXCR2CXCR1ALDH1A1EGFRERBB2 | |
| SCHEMBL6930050 | 0.77 | CXCR2 (0.44) | CXCR2CXCR1TRPV4RXFP1ALDH1A1 | |
| SCHEMBL7097896 | 0.69 | CXCR2 (0.45) | CXCR2CXCR1ALDH1A1 | |
| SCHEMBL7069157 | 0.69 | CXCR2 (0.70) | CXCR2CXCR1ALDH1A1KMT2A | |
| SCHEMBL6129921 | 0.66 | CXCR2 (0.47) | CXCR2CXCR1ALDH1A1EGFRERBB2 | |
| SCHEMBL6930935 | 0.64 | AR (0.37) | CXCR2CXCR1EGFRERBB2AR | |
| SCHEMBL27531046 | 0.62 | KAT2B (0.54) | ALDH1A1KMT2A | |
| SCHEMBL29710928 | 0.62 | TRPV4 (0.56) | TRPV4RXFP1ARKMT2A | |
| SCHEMBL31314271 | 0.62 | TRPV4 (0.46) | TRPV4ARKMT2A | |
| SCHEMBL6818586 | 0.61 | CXCR2 (0.46) | CXCR2CXCR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265905-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20030028042-A1 | Il8-receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-02-06 | — | — | US | disclosed |
| EP-1265905-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001064691-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028042-A1 | Il8-receptor antagonists | CXCL8, CCR8, IL1RN | CXCR2 28/4885CXCR1 37/4885TRPV4 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.